Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipapkinogene sovacivec - Transgene

Drug Profile

Tipapkinogene sovacivec - Transgene

Alternative Names: MVA-HPV-IL2 vaccine; R-3484; RG 3484; RO5217790; TG 4001

Latest Information Update: 31 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transgene
  • Developer European Organisation for Research and Treatment of Cancer; Merck & Co; Roche; Transgene
  • Class Cancer vaccines; Gene therapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Oropharyngeal cancer
  • Discontinued Cervical cancer; Cervical intraepithelial neoplasia; Head and neck cancer

Most Recent Events

  • 20 Dec 2018 Interim adverse events data from a phase I/II trial in Oropharyngeal cancer released by Transgene
  • 19 Sep 2017 Phase-I/II clinical trials in Oropharyngeal cancer (Combination therapy, Second-line therapy or greater) in France (SC) (NCT03260023)
  • 20 Mar 2017 Transgene, in collaboration with Merck and Pfizer, plans a phase II trial for HPV-positive Head and neck cancer in France in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top